Biologic therapies for the treatment of hidradenitis suppurativa

References

• Jemec GBE. Hidradenitis Suppurativa. N Engl J Med. 2012;366(2):158–164.
   PubMed Web of Science ®Google Scholar
• Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596–601.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol. 2009;60(4):539–561.
   PubMed Web of Science ®Google Scholar
• Machado MO, Stergiopoulos V, Maes M, et al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):939.
   PubMed Web of Science ®Google Scholar
• Horváth B, Janse IC, Sibbald GR. Pain management in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S47–51.
   PubMed Web of Science ®Google Scholar
• Hurley H. Axillary hyperhidrosis, aprocine bromhidrosis, hidradenitis suppurativa, and familia benign pemphigus: surgical approach. In: Roenigk R, Roenigk H, editors. dermatologic surgery: principles and practice. New York: Marcel Dekker, Inc; 1989. p. 713–748.
   Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–855.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434–1442.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211–213.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–1409.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–974.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434.
   PubMed Web of Science ®Google Scholar
• Laffert M, Von, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis*. Exp Dermatol. 2010;19(6):533–537.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105–115.
   PubMed Web of Science ®Google Scholar
• Thomi R, Cazzaniga S, Seyed Jafari SM, et al. Association of hidradenitis suppurativa with t helper 1/t helper 17 phenotypes: a semantic map analysis. JAMA Dermatol. 2018;154(5):592–595.
   PubMed Web of Science ®Google Scholar
• Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186(2):1228–1239.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Hänni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790–798.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292–1298.
   PubMed Web of Science ®Google Scholar
• Thomi R, Yerly D, Yawalkar N, et al. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol. 2017;177(5):1358–1366.
   PubMed Web of Science ®Google Scholar
• Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Res. 2018;7:1930.
   PubMedGoogle Scholar
• Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019;10:2040622319830646.
   Web of Science ®Google Scholar
• Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–150.
   PubMed Web of Science ®Google Scholar
• Kupetsky EA, Mathers AR, Ferris LK. Anti-cytokine therapy in the treatment of psoriasis. Cytokine. 2013;61(3):704–712.
   PubMed Web of Science ®Google Scholar
• Sabat R, Jemec GBE, Matusiak Ł, et al. Hidradenitis Suppurativa. Nat Rev Dis Primers. 2020. In Press.
   PubMed Web of Science ®Google Scholar
• Abbvie. Humira (adalimumab).
   Google Scholar
• van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166(2):298–305.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–69.e2.
   PubMed Web of Science ®Google Scholar
• Basra MKA, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatol (Basel). 2015;230(1):27–33.
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7(3):251–259.
   PubMed Web of Science ®Google Scholar
• Inc JB. Remicade (Infliximab).; 2013. [cited 2020 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103772s5385lbl.pdf.
   Google Scholar
• Katsanos KH, Christodoulou DK, Tsianos VE. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn’s disease patient. Am J Gastroenterol. 2002;97(8):2155–2156.
   PubMed Web of Science ®Google Scholar
• Blazquez I, Gonzalez-Lama Y, Roustan G. Crohn’s disease and hidradenitis suppurativa. An uncommon association that responds to infliximab. J Crohns Colitis. 2013;7(12):e717–718.
   PubMedGoogle Scholar
• Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn’s disease. J Dermatolog Treat. 2005;16(1):58–61.
   PubMed Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–217.
   PubMed Web of Science ®Google Scholar
• Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158(2):370–374.
   PubMed Web of Science ®Google Scholar
• Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702–708.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. mAbs. 2011;3(6):535–545.
   PubMed Web of Science ®Google Scholar
• Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006;177(7):4917–4926.
   PubMed Web of Science ®Google Scholar
• Inc JB. Stelara (Ustekinumab). 2012. [cited 2020 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf.
   Google Scholar
• Sharon V, Garcia M, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venerol. 2012;92(3):320–321.
   PubMed Web of Science ®Google Scholar
• Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839–846.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128.
   PubMed Web of Science ®Google Scholar
• Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatol (Basel). 2019 July;1–4. doi:10.1159/000501075.
   Web of Science ®Google Scholar
• Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26(7):911–914.
   PubMed Web of Science ®Google Scholar
• Baerveldt EM, Kappen JH, Thio HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behçet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72(4):626–627.
   PubMed Web of Science ®Google Scholar
• Chiu H-Y, Wang T-S, Chan -C-C, et al. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014;171(5):1181–1188.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med. 2011;269(1):16–28.
   PubMed Web of Science ®Google Scholar
• Sobi. Kineret (anakinra).
   Google Scholar
• Leslie KS, Tripathi VS, Nguyen VT, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(2):243–251.
   PubMed Web of Science ®Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52–59.
   PubMed Web of Science ®Google Scholar
• André R, Marescassier H, Gabay C, et al. Long-term therapy with anakinra in hidradenitis suppurativa in three patients. Int J Dermatol. 2019 July;58. doi:10.1111/ijd.14596.
   PubMed Web of Science ®Google Scholar
• Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656–666.
   PubMed Web of Science ®Google Scholar
• Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138(4):795–801.
   PubMed Web of Science ®Google Scholar
• A study of bermekimab in patients with hidradenitis suppurativa. ClinicalTrials.gov. [cited 2019 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03512275.
   Google Scholar
• A study to evaluate the efficacy, safety and tolerability of bermekimab in patients with hidradenitis suppurativa. ClinicalTrials.gov. [cited 2019 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04019041.
   Google Scholar
• Novartis. Cosentyx (Secukinumab). [cited 2020 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125504s000lbl.pdf.
   Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. Sep 2019. doi:10.1111/bjd.17822.
   PubMed Web of Science ®Google Scholar
• Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182–185.
   PubMed Web of Science ®Google Scholar
• Schuch A, Fischer T, Boehner A, et al. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Dermatol Venereologica. 2018;98(1):151–152.
   PubMed Web of Science ®Google Scholar
• Jørgensen A-HR, Yao Y, Thomsen SF. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018;2018:1–3.
   Google Scholar
• Marasca C, Megna M, Balato A, et al. Secukinumab and hidradenitis suppurativa: friends or foes. JAAD Case Rep. 2019;5(2):184–187.
   PubMedGoogle Scholar
• ClinicalTrials.gov. Exploratory trial evaluating cosentyx (secukinumab) for patients with moderate-to severe hidradenitis suppurativa. identifier: [cited 2019 Oct 15]. NCT 03099980. https://clinicaltrials.gov/ct2/show/NCT03099980?cond=Hidradenitis+Suppurativa&draw=1&rank=17.
   Google Scholar
• ClinicalTrials.gov. Study of efficacy and safety of two secukinumab dose regimens in subjects with moderate to severe hidradenitis suppurativa (HS) (SUNRISE). [cited 2019 Oct 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03713632?cond=Hidradenitis+Suppurativa&rank=12.
   Google Scholar
• ClinicalTrials.gov. this is a study of efficacy and safety of two secukinumab dose regimens in subjects with moderate to severe hidradenitis suppurativa (HS). (SUNSHINE). [cited 2019 Oct 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03713619?cond=Hidradenitis+Suppurativa&rank=13.
   Google Scholar
• Inc JB. Tremfya (Guselkumab). 2017. [cited 2020 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf.
   Google Scholar
• Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33(3):e140–e141.
   PubMed Web of Science ®Google Scholar
• Berman H, Villa NM, Shi VY, et al. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J Dermatolog Treat. 2019 August;1–9. doi:10.1080/09546634.2019.1654067.
   PubMed Web of Science ®Google Scholar
• Casseres RG, Kahn JS, Her MJ, et al. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review. J Am Acad Dermatol. 2019;81(1):265–267.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy, safety and tolerability of guselkumab for the treatment of participants with moderate to severe hidradenitis suppurativa (HS) (NOVA). identifier NCT03628924. [cited 2019 Oct 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03628924?cond=hidradenitis+suppurativa&rank=13.
   Google Scholar
• Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. ClinicalTrials.gov. [cited 2019 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04061395.
   Google Scholar
• Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab. ClinicalTrials.gov. [cited 2019 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04084665. .
   Google Scholar
• ClinicalTrials.gov. Assessment of the safety, tolerability and efficacy of medi8968 in subjects with moderate to severe hidradenitis suppurativa.
   Google Scholar
• Etanercept for Treatment of Hidradenitis. ClinicalTrials.gov. [cited 2019 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT00107991.
   Google Scholar
• Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60(4):565–573.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to test the efficacy, safety and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativa. Identifier: NCT03248531.
   Google Scholar
• ClinicalTrials.gov. Efficacy, safety, and pharmacokinetic study of CJM112 in hidradenitis suppurativa patients. Identifier: NCT02421172.
   Google Scholar
• A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa. ClinicalTrials.gov. [cited 2019 Aug 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03926169
   Google Scholar
• Treatment of moderate hidradenitis suppurativa. ClinicalTrials.gov. [cited 2019 August 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03910803
   Google Scholar
• Biomarkers in hidradenitis suppurativa participants receiving brodalumab. ClinicalTrials.gov. [cited 2019 Aug 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03960268
   Google Scholar
• Flood KS, Porter ML, Kimball AB. Biologic Treatment for hidradenitis suppurativa. Am J Clin Dermatol. 2019May;20:625–638. .
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Studying complement inhibition in patients with moderate to severe hidradenitis suppurativa. Identified: NCT03001622.
   Google Scholar
• Giamarellos-Bourboulis MD. Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody, in a open-label, phase 2a study in patient with severe hidradenitis suppurative not eligible for adalimumab. presented at the: AAD. 2018. https://www.aadhighlights2018.com/articles/efficacy-and-safety-of-ifx/read.
   Google Scholar
• N.V I. InflaRx announces top-line shine phase iib results for ifx-1 in hidradenitis suppurativa. Globenewswire news room. [ updated 2019 June 5; cited 2019 Oct 15]. Available from: http://www.globenewswire.com/news-release/2019/06/05/1864534/0/en/InflaRx-Announces-Top-Line-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa.html.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety study of IFX-1 in patients with moderate to severe hidradenitis suppurativa (HS) (SHINE). Identifier: NCT03487276.
   Google Scholar
• ClinicalTrials.gov. Study of efficacy and safety of investigational treatments in patients with moderate to severe hidradenitis suppurativa. [cited 2019 Oct 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03827798?cond=hidradenitis+suppurativa&rank=3.
   Google Scholar
• Safety and pharmacokinetics of repeat doses of csl324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. ClinicalTrials.gov. [ cited 2019 Aug 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03972280
   Google Scholar
• Comparison of PK an d tolerability of MSB11022 administered by AI or PFS. ClinicalTrials.gov. [ cited 2019 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04018599
   Google Scholar
• Garg A, Kirby JS, Lavian J, et al. Sex-and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760–764.
   PubMed Web of Science ®Google Scholar
• Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77(1):118–122.
   PubMed Web of Science ®Google Scholar
• Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Women Dermatol. 2017;3(1):21–25.
   PubMedGoogle Scholar
• De Simone C, Caldarola G, Moretta G, et al. Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. G Ital Dermatol Venereol. 2019;154(3). doi:10.23736/S0392-0488.18.06255-7
   Web of Science ®Google Scholar
• Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248–255.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33(9):1053–1058.
   PubMed Web of Science ®Google Scholar
• Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol. 2012;94(8):607–611.
   PubMed Web of Science ®Google Scholar
• Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Womens Health. 2010;2:199–209.
   PubMedGoogle Scholar
• Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–119.
   PubMed Web of Science ®Google Scholar
• Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13(12):1699–1708.
   PubMed Web of Science ®Google Scholar
• Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11(10):1240.
   PubMed Web of Science ®Google Scholar
• Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016;30(3):488–490.
   PubMed Web of Science ®Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, et al. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012;6(4):105–107.
   PubMedGoogle Scholar
• Watson N, Wu K, Farr P, et al. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. Br J Dermatol. 2019;180(1):195–196.
   PubMed Web of Science ®Google Scholar
• Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis. 2018;12(3):376–378.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, et al. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient. Dermatol Ther. 2019;32(3):e12895.
   PubMed Web of Science ®Google Scholar
• Youngstein T, Hoffmann P, Gül A, et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology (Oxford). 2017;56(12):2102–2108.
   PubMed Web of Science ®Google Scholar
• Smith CJF, Chambers CD. Five successful pregnancies with antenatal anakinra exposure. Rheumatology (Oxford). 2018April;57:1271–1275. .
   Web of Science ®Google Scholar
• Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205–1207.
   PubMed Web of Science ®Google Scholar
• Matro R, Martin CF, Wolf D, et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155(3):696–704.
   PubMed Web of Science ®Google Scholar
• Micu MC, Micu R, Surd S, et al. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology (Oxford). 2014;53(7):1250–1255.
   PubMed Web of Science ®Google Scholar
• Winger EE, Reed JL, Ashoush S, et al. Degree of TNF-α/IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with Adalimumab (Humira) and IVIG. Am J Reprod Immunol. 2011;65(6):610–618.
   PubMed Web of Science ®Google Scholar
• Winger EE, Reed JL, Ashoush S, et al. Treatment with Adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2009;61(2):113–120.
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Tzanetakou V, Zisimou C, et al. A retrospective study of the characteristics of patients with early-onset compared to adult-onset hidradenitis suppurativa. Int J Dermatol. 2018;57(6):687–691.
   PubMed Web of Science ®Google Scholar
• Bi Y, Liu J, Wang J, et al. Model-informed drug development approach supporting approval of adalimumab (humira) in adolescent patients with hidradenitis suppurativa: a regulatory perspective. Aaps J. 2019;21(5):91.
   PubMed Web of Science ®Google Scholar
• Oranges T, Chiricozzi A, Iannone M, et al. long-term outcome of adalimumab in a young girl with hidradenitis suppurativa. Skin Appendage Disord. 2018;5(1):38–41.
   PubMed Web of Science ®Google Scholar
• Baldassano RN. Infliximab in pediatric crohn’s disease patients. Gastroenterol Hepatol. 2006;2(7):467.
   PubMedGoogle Scholar
• Landells I, Marano C, Hsu M-C, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Provini LE, Stellar JJ, Stetzer MN, et al. Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa. Pediatr Dermatol. 2019;36(3):381–383.
   PubMed Web of Science ®Google Scholar
• Kim SR, Kibbi N, Craiglow BG. Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient. JAAD Case Rep. 2019;5(6):552–554.
   PubMedGoogle Scholar
• Köstner K, Prelog M, Almanzar G, et al. Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology (Oxford). 2018;57(5):936–938.
   PubMed Web of Science ®Google Scholar
• Wells LE, Evans T, Hilton R, et al. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. Pediatr Dermatol. 2019;36(3):384–385.
   PubMed Web of Science ®Google Scholar
• Cline A, Bartos GJ, Strowd LC, et al. Biologic treatment options for pediatric psoriasis and atopic dermatitis. Children. 2019;6(9):103.
   Google Scholar
• Gallitano SM, McDermott L, Brar K, et al. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74(5):974–980.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
   PubMed Web of Science ®Google Scholar
• Molina-Leyva A, Badiola J. Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient. AIDS. 2018;32(16):2436–2438.
   PubMed Web of Science ®Google Scholar
• Alecsandru D, Padilla B, Izquierdo JAA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146(12):1343–1345.
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Fernandez-Pugnaire M-A, Ruiz-Carrascosa J-C. Severe hidradenitis suppurative in an HIV-positive male: use of multiple treatment modalities, including tumor necrosis factor blockade. AIDS Patient Care STDS. 2011;25(9):507–508.
   PubMed Web of Science ®Google Scholar
• Saeki H, Ito T, Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015;29(8):1653–1655.
   PubMed Web of Science ®Google Scholar
• Paparizos V, Rallis E, Kirsten L, et al. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat. 2012;23(6):398–399.
   PubMed Web of Science ®Google Scholar
• Bartos G, Cline A, Beroukhim K, et al. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018 Nov ;24(11):2.
   PubMedGoogle Scholar
• Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Dtsch Dermatol Ges. 2019;17(6):646–648.
   Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Santos-Pérez MI, García-Rodicio S, Del Olmo-Revuelto MA, et al. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermo-Sifiliográficas. 2014;105(7):720–722.
   PubMedGoogle Scholar
• Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31(11):1853–1859.
   PubMed Web of Science ®Google Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88–97.e5.
   PubMed Web of Science ®Google Scholar
• Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168(3):609–616.
   PubMed Web of Science ®Google Scholar
• Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90(6):359–371.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Fukae J, Fukaya S, et al. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2019;22(4):574–582.
   PubMed Web of Science ®Google Scholar
• Siegel SAR, Winthrop KL, Ehst BD, et al. Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C. Br J Dermatol. 2019;180(5):1232–1233.
   PubMed Web of Science ®Google Scholar
• Chiu H-Y, Chen C-H, Wu M-S, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169(6):1295–1303.
   PubMed Web of Science ®Google Scholar
• Ting S-W, Chen Y-C, Huang Y-H. Risk of hepatitis b reactivation in patients with psoriasis on ustekinumab. Clin Drug Investig. 2018;38(9):873–880.
   PubMed Web of Science ®Google Scholar
• Chiu H-Y, Hui RC-Y, Huang Y-H, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829–834.
   PubMed Web of Science ®Google Scholar
• Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol. 2018;32(3):e120–e121.
   PubMed Web of Science ®Google Scholar
• Feaster B, Cline A, Feldman SR. Secukinumab for psoriasis in a patient with hepatitis B. Dermatol Online J. 2018 Sep;24(9):15.
   PubMedGoogle Scholar
• Peccerillo F, Odorici G, Pellacani G, et al. Secukinumab:A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. Dermatol Ther. 2018;31(4):e12601.
   PubMed Web of Science ®Google Scholar
• Yanagihara S, Sugita K, Yoshida Y, et al. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol. 2017;27(2):185–186.
   PubMed Web of Science ®Google Scholar
• Jennings L, Molloy O, Quinlan C, et al. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier. Int J Dermatol. 2017;56(6):e128–e129.
   PubMed Web of Science ®Google Scholar
• Constantin MM, Cristea CM, Taranu T, et al. Biosimilars in dermatology: the wind of change. Exp Ther Med. 2019;18(2):911–915.
   PubMed Web of Science ®Google Scholar
• Markus R, McBride HJ, Ramchandani M, et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar abp 501. Adv Ther. 2019;36(8):1833–1850.
   PubMed Web of Science ®Google Scholar
• Barker J, Girolomoni G, Egeberg A, et al. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat. 2019 May;1–7. doi:10.1080/09546634.2019.1610553.
   PubMedGoogle Scholar
• Patil S. Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa. Indian J Dermatol Venereol Leprol. 2018;84(6):745–747.
   PubMed Web of Science ®Google Scholar
• Humira EMA Package insert. [cited 2019 Oct 14]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf.
   Google Scholar
• Salamon M Painful Inflamed skin helped with stronger drug dosing. Medscape. [ updated 2019 Feb 11; cited 2019 Oct 15]. Available from: https://www.medscape.com/viewarticle/908922
   Google Scholar
• Sapadin AN, Fleischmajer R. Tetracyclines:nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258–265.
   PubMed Web of Science ®Google Scholar
• Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5):S42–S46.
   PubMed Web of Science ®Google Scholar
• Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325–328.
   PubMed Web of Science ®Google Scholar
• Mendonça CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154(5):977–978.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Bigby M. Rifampinand clindamycin are safe long term response to north American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian hidradenitis suppurativa foundations part ii: topical, intralesional, and systemic medical management. J Am Acad Dermatol. September 2019. doi:10.1016/j.jaad.2019.08.088.
   Web of Science ®Google Scholar